Effects of Aldose Reductase Inhibitors on the Progression of Nerve Damage

D. Greene,A. Sima

DOI: https://doi.org/10.1111/j.1464-5491.1993.tb00194.x

IF: 3.5

1993-06-01

Diabetic Medicine

Abstract:Ever since nerve degeneration and demyelination were implicated in the development of diabetic neuropathy, much attention has been focused on the role of the polyol pathway, and in particular the enzyme aldose reductase, in the development of this devastating diabetic complication. In the nerve, the accumulation of sorbitol has been linked with depletion of myo-inositol, decreased sodium-potassium ATPase activity and energy utilization, and slowed motor nerve conduction velocity,' leading to characteristic morphometric changes such as axo-glial dysjunction.2 Therefore, the ability to inhibit this sorbitol accumulation pharmacologically could represent an opportunity to reverse the nerve damage associated with these metabolic alterations. Aldose reductase inhibitors have been shown to prevent or reverse the metabolic and even structural changes found in the nerves of diabetic rat model^.^ However, their effectiveness in treating clinically overt human diabetic neuropathy has been questionable. Short-term trials of various aldose reductase inhibitors have been inconclusive at best."6 However, three long-term trials have recently been completed for morphometric analysis and have yielded some meaningful insight into the best means to investigate the effects of aldose reductase inhibitors on nerve fiber morphology. The Sorbinil North American Neuropathy Trial was a 12-month, double-blind, randomized, controlled study testing the effectiveness of the Pfizer aldose reductase inhibitor sorbinil.2 At one centre in Toronto, Canada, a total of 16 diabetic patients with symptomatic peripheral neuropathy of at least 1 year duration underwent nerve biopsy at the start of study and after 1 year of treatment with either the active drug (250 mg day-', n = 10) or placebo (n = 6). Biochemical analysis of the nerves revealed a statistically significant decrease in sorbitol level in the treated patients versus no change in the placebo patients. Morphometric findings consisted of a partial correction of nerve fibre loss in the treated patients exhibited by an increase in fibre density accompanied by a four-fold increase in fibre regeneration. No such changes were observed in the placebo patients. A number of other lesions specific to nerve fibres, such as axoglial dysjunction, were increased at baseline in both groups and corrected towards normal in the sorbinil-